Polypharmacy and Medicines to Avoid
The number of individuals surviving past age 65 is increasing globally and the likelihood of suffering from chronic diseases is also rising as the demographics shift. Since even a single medical condition may require multiple medications, it is not surprising that each additional disease significantly increases the risk for polypharmacy-related adverse drug reactions (ADRs) and morbidity. This is especially so when each comorbidity requires the care of a different specialist as is frequently seen in the aged population.
KeywordsDementia Paclitaxel Levodopa Propranolol Verapamil
The author wishes to thank Andrea Gomez, MD and Mary-Rita Blute, RN for their assitance during the preparation of this chapter.
- de Abajo FJ, Garcia–Rodriguez LA. Risk of upper gastrointestinal track bleeding associated with selective serotonin reuptake inhibitors and venlafaxine, therapy: interaction with non–steroidal anti–inflammatory drugs and effect of acid–suppressing agents. Arch Gen Psychiatry. 2008;65;795–803.PubMedCrossRefGoogle Scholar
- Heaver JF. Polypharmacy. In: Sieber, FE, ed. Geriatric anesthesia. The McGraw–Hill Companies, Inc; 2007:163–172.Google Scholar
- Lyrica(Pregabalin)[package insert].New York, NY:Pfizer;2006.Google Scholar
- Moitra V, Diaz G, Sladen RN. Monitoring hepatic function. In Fleisher LA, cons.ed: Anesthesiology Clin: monitoring. WB. Saunders Inc. 2006;24:857–880.Google Scholar
- SFINX drug interactions. http://www.terveysportti.%01/s%01nx/.